FGFR3-TACC3 fusion is an activating rearrangement in urothelial carcinoma (~2-3%). Includ...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR3-TACC3-UROTHELIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-CIVIC SRC-EAU-BLADDER-2024 SRC-NCCN-BLADDER-2025 |
Actionability Facts
| Biomarker | BIO-FGFR3-MUTATION |
|---|---|
| Variant | FGFR3-TACC3 fusion |
| Disease | DIS-UROTHELIAL |
| ESCAT tier | IA |
| Recommended combinations | erdafitinib monotherapy |
| Evidence summary | FGFR3-TACC3 fusion is an activating rearrangement in urothelial carcinoma (~2-3%). Included in the erdafitinib companion-diagnostic FGFR alteration list. Erdafitinib responses in fusion-positive patients are comparable to those in mutation-positive (THOR, BLC2001). |
Notes
ESCAT IA. RNA-NGS preferred for fusion detection; some DNA panels miss intronic breakpoints.
Used By
No reverse references found in the YAML corpus.